ATO, approved since 2000 for the treatment of acute promyelocytic leukemia, directly binds to PML proteins, thereby massively changing the amount of PML-NBs in the cell and probably changing the composition of the remaining bodies and deregulating the SUMO pool of the host cell (48, 51, 56, 60, –, 63). Here, PML is linked to acute promyelocytic leukemia.